Retrospective cohort study estimates disease-free and overall survival in high-risk endometrial cancer patients, indicating significant recurrence rates.
Key Points
Overall survival from adjuvant therapy initiation was estimated at 8.85 years, indicating the long-term prognosis for patients.
Approximately 45% of participants experienced disease recurrence, underscoring the need for effective management strategies.
The study involved 6036 women and utilized data from Public Health England's National Cancer Registration and Analysis Service.
The results highlight the unmet medical needs and clinical burden faced by high-risk endometrial cancer patients.